https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Harnessing technology to enable all women mobility in labour and birth: feasibility of implementing beltless non-invasive fetal ECG applying the NASSS framework https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48604 Wed 22 Mar 2023 08:53:58 AEDT ]]> PTGS2 (Prostaglandin Endoperoxide Synthase-2) expression in term human amnion in vivo involves rapid mRNA turnover, polymerase-II 5'-pausing, and glucocorticoid transrepression https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15716 Wed 11 Apr 2018 17:09:52 AEST ]]> Moxibustion for cephalic version: a feasibility randomised controlled trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14329 Wed 11 Apr 2018 12:15:55 AEST ]]> 'Seeing the baby': pleasures and dilemmas of ultrasound technologies for primiparous Australian women https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1913 Wed 11 Apr 2018 09:29:43 AEST ]]> The Breathing for Life Trial: a randomised controlled trial of fractional exhaled nitric oxide (FENO)-based management of asthma during pregnancy and its impact on perinatal outcomes and infant and childhood respiratory health https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25524 29 parts per billion (ppb), decrease in dose when FENO <19 ppb, and no change when FENO is between 19 and 29 ppb). A long acting beta agonist (LABA) will be added when symptoms remain uncontrolled. Both the control and intervention groups will report on exacerbations at a postpartum phone interview. The primary outcome is adverse perinatal outcome (a composite measure including preterm birth, intrauterine growth restriction, neonatal hospitalisation at birth or perinatal mortality), assessed from hospital records. Secondary outcomes will be each component of the primary outcome, maternal exacerbations requiring medical intervention during pregnancy (both smokers and non-smokers), and hospitalisation and emergency department presentation for wheeze, bronchiolitis or croup in the first 12 months of infancy. Outcome assessment and statistical analysis of the primary outcome will be blinded. To detect a reduction in adverse perinatal outcomes from 35 % to 26 %, 600 pregnant women with asthma per group are required. Discussion: This trial will provide evidence for the effectiveness of a FENO-based management strategy in improving perinatal outcomes in pregnant women with asthma. If successful, this would improve the management of pregnant women with asthma worldwide.]]> Thu 17 Mar 2022 14:41:14 AEDT ]]> Holistic physiological care compared with active management of the third stage of labour for women at low risk of postpartum haemorrhage: a cohort study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:9701 Sat 24 Mar 2018 08:34:37 AEDT ]]> Neonatal neurodevelopmental outcomes following tocolysis with glycerol trinitrate patches https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1118 Sat 24 Mar 2018 08:32:00 AEDT ]]> Supporting women planning a vaginal breech birth: an international survey https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29055 Sat 24 Mar 2018 07:37:18 AEDT ]]> Characterization of human fetal cord blood steroid profiles in relation to fetal sex and mode of delivery using temperature-dependent inclusion chromatography and principal component analysis (PCA) https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:3496 Sat 24 Mar 2018 07:20:35 AEDT ]]> Longitudinal Analysis of Lung Function in Pregnant Women with and without Asthma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49544 Mon 22 May 2023 08:45:35 AEST ]]> Effect of asthma management with exhaled nitric oxide versus usual care on perinatal outcomes https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47321 Fri 13 Jan 2023 11:06:47 AEDT ]]>